Harnessing the self-assembly of peptides for the targeted delivery of anti-cancer agents,Materials Horizons

当前位置： X-MOL 学术 › Mater. Horiz. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Harnessing the self-assembly of peptides for the targeted delivery of anti-cancer agents
Materials Horizons ( IF 12.2 ) Pub Date : 2020-05-28 , DOI: 10.1039/d0mh00398k
Stephanie J. Franks _{1,

2,

3,

4,

5} , Kate Firipis _{6,

7,

8,

9,

10} , Rita Ferreira _{5,

10,

11,

12,

13} , Katherine M. Hannan _{5,

10,

11,

12,

13} , Richard J. Williams _{6,

7,

8,

9,

10} , Ross D. Hannan _{5,

10,

11,

12,

13} , David R. Nisbet _{1,

2,

3,

4,

5}

Affiliation

A significant challenge to current cancer drug treatment is mode of delivery, both in terms of efficacy and off-target toxicity to healthy tissues. To overcome this, drug localisation using a range of biocompatible carriers is currently in use or under investigation. One class of these biomaterial carriers that offers a unique prospect for use as drug delivery vectors to tumour sites is hydrogels formed by small molecules. In particular, tissue mimetic self-assembling molecular hydrogels can function either as injectable precursors that gelate in response to tumour-specific markers, or as implants in conjunction with surgical resection or tumour debulking. Their inherent biocompatibility, tuneable properties, and capacity to flow and gelate in situ allow them to effectively transport, hold and release therapeutic molecules in a spatially and temporally controlled manner. This has been shown in a number of in vitro and in vivo studies, where they improve anti-cancer efficacy while reducing non-specific toxicity. However, further investigation is required to optimise these systems toward both the drug and the target tissue, to provide sophisticated temporal control over the drug presentation, and to determine the most effective drug–material combinations for specific cancer types and locations.

中文翻译：

利用肽的自组装来靶向递送抗癌药

当前的癌症药物治疗的一个重大挑战是递送方式，无论是在功效还是对健康组织的脱靶毒性方面。为了克服这个问题，目前正在使用或正在研究使用多种生物相容性载体进行药物定位。一类由小分子形成的水凝胶为这些生物材料载体提供了独特的前景，可作为药物输送到肿瘤部位的载体。特别地，组织模拟自组装分子水凝胶既可以用作可注射的前体，其可响应于肿瘤特异性标记而凝胶化，也可以用作与外科手术切除或肿瘤切除术结合的植入物。它们固有的生物相容性，可调节的特性以及原位流动和凝胶化的能力使它们能够以空间和时间控制的方式有效地运输，保持和释放治疗分子。这已在许多体外和体内研究中得到证实，它们在提高抗癌功效的同时降低了非特异性毒性。但是，需要进一步研究以优化针对药物和靶组织的这些系统，对药物的呈递提供复杂的时间控制，并确定针对特定癌症类型和位置的最有效药物-材料组合。

更新日期：2020-08-03

点击分享查看原文

点击收藏

阅读更多本刊最新论文本刊介绍/投稿指南11